Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2 Hydroxypropyl Beta Cyclodextrin
2. 2 Hydroxypropyl-beta-cyclodextrin
3. 2-hydroxypropyl-beta-cyclodextrin
4. Beta Hydroxypropylcyclodextrin
5. Beta-hydroxypropylcyclodextrin
6. Betadex, Hydroxypropyl
7. Hp-beta-cd
8. Hpbetacd
9. Hydroxypropyl Beta Cyclodextrin
10. Hydroxypropyl Betadex
11. Hydroxypropyl-beta-cyclodextrin
1. 107745-73-3
2. Hp-beta-cd
3. 2-hydroxypropyl-
4. A-cyclodextrin
5. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrin
6. Trappsol Hpb
7. Hydroxypropylbetadex
8. Thpb
9. Hydroxypropyl-beta-cyclodextri
10. Hydroxypropyl-beta Cyclodextrin
11. Chembl577294
12. Dtxsid401017375
13. .beta.-cyclodextrin, 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-
14. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrinr
Molecular Weight | 1541.5 g/mol |
---|---|
Molecular Formula | C63H112O42 |
XLogP3 | -13 |
Hydrogen Bond Donor Count | 21 |
Hydrogen Bond Acceptor Count | 42 |
Rotatable Bond Count | 28 |
Exact Mass | 1540.6628176 g/mol |
Monoisotopic Mass | 1540.6628176 g/mol |
Topological Polar Surface Area | 619 Ų |
Heavy Atom Count | 105 |
Formal Charge | 0 |
Complexity | 2010 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 35 |
Undefined Atom Stereocenter Count | 7 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Excipients
Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. (See all compounds classified as Excipients.)
Details:
The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 22, 2024
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
Details : The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.
Brand Name : Trappsol Cyclo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 22, 2024
Details:
Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cyclo Therapeutics Completes Enrollment in Phase 3 TransportNPC™ Trial
Details : Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.
Brand Name : Trappsol Cyclo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2024
Details:
VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Brand Name: VAR 200
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ZyVersa Gets IRB Approval for Phase 2a Trial Of VAR 200 in Diabetic Kidney Disease
Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.
Brand Name : VAR 200
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2024
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 27, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 27, 2023
Details:
Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 18, 2023
Details:
VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alport syndrome.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Nephrology Brand Name: VAR 200
Study Phase: Phase IProduct Type: Large molecule
Sponsor: George Clinical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : George Clinical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alp...
Brand Name : VAR 200
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 14, 2023
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Cyclo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 21, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Cyclo Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 21, 2023
Details:
Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal and Alzheimer’s disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Rafael Holdings
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Rafael Holdings
Deal Size : $5.0 million
Deal Type : Private Placement
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
Details : Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal an...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 02, 2023
Details:
Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Rafael Holdings
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 05, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Rafael Holdings
Deal Size : $5.0 million
Deal Type : Private Placement
Details : Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fa...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 05, 2023
Details:
Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease and NPC1.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
Details : Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease a...
Brand Name : Trappsol Cyclo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 11, 2023
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?